How were Mabvax Therapeutics' earnings last quarter?

Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.62) earnings per share (EPS) for the quarter.

When did Mabvax Therapeutics' stock split?

Mabvax Therapeutics's stock reverse split before market open on Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2018. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What other stocks do shareholders of Mabvax Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mabvax Therapeutics investors own include Immunomedics (IMMU) , GW Pharmaceuticals (GWPH) , Athersys (ATHX) , Dollar General (DG) , Gilead Sciences (GILD) , Zynerba Pharmaceuticals (ZYNE) , Depomed (DEPO) , Galectin Therapeutics (GALT) and

NASDAQ:MBVX

Mabvax Therapeutics (MBVX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free MBVX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.01
▼
$1.15
52-Week Range: N/A

Volume: 1,333 shs
Average Volume: 31,620 shs
Market Capitalization: $213,000.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Mabvax Therapeutics alerts:

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Mabvax Therapeutics

MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

MBVX Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive MBVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mabvax Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2017
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MBVX
Previous Symbol: OTCMKTS:TELKD
CUSIP: N/A
CIK: 1109196
Web: www.mabvax.com
Phone: 858-259-9405
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 9,255,000
Free Float: N/A
Market Cap: $213,000.00
Optionable: Not Optionable
Beta: N/A

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. John David Hansen (Age 67)
Chairman, Pres & CEO
Prof. Philip O. Livingston (Age 75)
Co-Founder, Chief Science Officer & Director
Mr. Gregory P. Hanson C.M.A. (Age 71)
M.B.A., MBA, CMA, Chief Financial Officer
Dr. Paul W. Maffuid (Age 63)
Exec. VP of R&D
Dr. Paul F. Resnick (Age 61)
VP & Chief Bus. Officer

Key Competitors

View All Competitors

MBVX Stock Analysis - Frequently Asked Questions

How were Mabvax Therapeutics' earnings last quarter?: Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) posted its quarterly earnings data on Tuesday, November, 7th. The company reported ($1.62) earnings per share (EPS) for the quarter.
When did Mabvax Therapeutics' stock split?: Mabvax Therapeutics's stock reverse split before market open on Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 15th 2018. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.
What other stocks do shareholders of Mabvax Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mabvax Therapeutics investors own include Immunomedics (IMMU), GW Pharmaceuticals (GWPH), Athersys (ATHX), Dollar General (DG), Gilead Sciences (GILD), Zynerba Pharmaceuticals (ZYNE), Depomed (DEPO), Galectin Therapeutics (GALT) and

This page (NASDAQ:MBVX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mabvax Therapeutics (MBVX) Stock Price, News & Analysis

About Mabvax Therapeutics

MBVX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MBVX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info